Q1 2024
Released Aug 10, 2023, before the open
10-Q filed Aug 10, 2023, 41 days after period end · 0001764013-23-000092
Q1 2024 · 10-Q
Revenue—
Net Income-$73.94M-$73.94M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.57-$0.57 N/M vs Q1 2023no prior Q4 2023 on file
Operating Cash Flow-$47,370,000N/M
Free Cash Flowderived-$47,415,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2019 |
|---|---|---|---|---|
| Net Income | -$73.94M | -$40.37M | -$30.47M | -$20.06M |
| EPS Diluted | -$0.57 | -$0.35 | -$0.31 | -$0.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR